
Charles River Laboratories International CRL
€ 144.31
3.11%
Geschäftsbericht 2025
hinzugefügt 18.02.2026
Charles River Laboratories International Abschreibung & Amortisation 2011-2026 | CRL
Abschreibung & Amortisation Jährlich Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 403 M | 362 M | 314 M | 304 M | 266 M | 235 M | 198 M | 162 M | 131 M | 127 M | 94.9 M | 96.4 M | 96.6 M | 81.3 M | 85.2 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 403 M | 81.3 M | 197 M |
Abschreibung & Amortisation Vierteljährlich Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.2 M | 120 M | 120 M | - | 88.2 M | 86.1 M | 85.4 M | - | 78.9 M | 77.7 M | 77.1 M | - | 74.6 M | 76.4 M | 75.3 M | - | 68.7 M | 68.1 M | 61.5 M | - | 59.6 M | 57.2 M | 57.3 M | - | 51.8 M | 49.1 M | 45.4 M | - | 43.6 M | 43.4 M | 33.2 M | - | 33.5 M | 31.8 M | 32.4 M | - | 34.1 M | 32.4 M | 24.7 M | - | 23.8 M | 23.1 M | 22.4 M | - | 26.1 M | 24.3 M | 20 M | - | 67.3 M | 40.4 M | 20 M | - | 60.6 M | 40.1 M | 20 M | - | 64.2 M | 43.1 M | 21.3 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 120 M | 20 M | 53.1 M |
Abschreibung & Amortisation anderer Aktien in der Diagnostik & Forschung
| Name | Abschreibung & Amortisation | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
264 K | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 29.0 | -3.07 % | $ 316 M | ||
|
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
14 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
130 K | $ 104.95 | -1.72 % | $ 4.14 B | ||
|
Co-Diagnostics
CODX
|
1.23 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
721 M | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
16 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | ||
|
Quest Diagnostics Incorporated
DGX
|
493 M | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
DexCom
DXCM
|
252 M | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
473 K | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
14.4 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
354 M | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
24.9 M | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
125 M | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
64.6 M | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
39.7 M | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
488 M | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
300 K | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
203 M | - | - | $ 10.6 B | ||
|
IDEXX Laboratories
IDXX
|
130 M | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
1.14 B | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Biodesix
BDSX
|
5.77 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Laboratory Corporation of America Holdings
LH
|
644 M | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
87 K | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
57.4 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
27.2 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | ||
|
National Research Corporation
NRC
|
140 K | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 378.44 | 0.14 % | $ 28.4 B |